Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Tanja Dolinšek) .

1 - 10 / 24
Na začetekNa prejšnjo stran123Na naslednjo stranNa konec
1.
Safety and efficacy of IL-12 plasmid DNA transfection into pig skin : supportive data for human clinical trials on gene therapy and vaccination
Urša Lampreht Tratar, Tanja Jesenko, Maša Omerzel, Alenka Seliškar, Urban Stupan, Mihajlo Djokić, Jerneja Sredenšek, Blaž Trotovšek, Gregor Serša, Maja Čemažar, 2024, izvirni znanstveni članek

Povzetek: Gene electrotransfer (GET) of plasmids encoding interleukin 12 (IL-12) has already been used for the treatment of various types of tumors in human oncology and as an adjuvant in DNA vaccines. In recent years, we have developed a plasmid encoding human IL-12 (phIL12) that is currently in a phase I clinical study. The aim was to confirm the results of a non-clinical study in mice on pharmacokinetic characteristics and safety in a porcine model that better resembled human skin. The GET of phIL12 in the skin was performed on nine pigs using different concentrations of plasmid phIL12 and invasive (needle) or noninvasive (plate) types of electrodes. The results of our study demonstrate that the GET of phIL-12 with needle electrodes induced the highest expression of IL-12 at the protein level on day 7 after the procedure. The plasmid was distributed to all tested organs; however, its amount decreased over time and was at a minimum 28 days after GET. Based on plasmid copy number and expression results, together with blood analysis, we showed that IL-12 GET is safe in a porcine animal model. Furthermore, we demonstrated that pigs are a valuable model for human gene therapy safety studies.
Ključne besede: interleukin 12, gene electrotransfer, immunotherapy
Objavljeno v DiRROS: 18.04.2024; Ogledov: 18; Prenosov: 11
.pdf Celotno besedilo (16,83 MB)
Gradivo ima več datotek! Več...

2.
Effects of electrochemotherapy on immunologically important modifications in tumor cells
Urša Kešar, Boštjan Markelc, Tanja Jesenko, Katja Uršič Valentinuzzi, Maja Čemažar, Primož Strojan, Gregor Serša, 2023, izvirni znanstveni članek

Povzetek: Electrochemotherapy (ECT) is a clinically acknowledged method that combines the use of anticancer drugs and electrical pulses. Electrochemotherapy with bleomycin (BLM) can induce immunogenic cell death (ICD) in certain settings. However, whether this is ubiquitous over different cancer types and for other clinically relevant chemotherapeutics used with electrochemotherapy is unknown. Here, we evaluated in vitro in the B16-F10, 4T1 and CT26 murine tumor cell lines, the electrochemotherapy triggered changes in the ICD-associated damage-associated molecular patterns (DAMPs): Calreticulin (CRT), ATP, High Mobility Group Box 1 (HMGB1), and four immunologically important cellular markers: MHCI, MHC II, PD-L1 and CD40. The changes in these markers were investigated in time up to 48 h after ECT. We showed that electrochemotherapy with all three tested chemotherapeutics induced ICD-associated DAMPs, but the induced DAMP signature was cell line and chemotherapeutic concentration specific. Similarly, electrochemotherapy with CDDP, OXA or BLM modified the expression of MHC I, MHC II, PD-L1 and CD40. The potential of electrochemotherapy to change their expression was also cell line and chemotherapeutic concentration specific. Our results thus put the electrochemotherapy with clinically relevant chemotherapeutics CDDP, OXA and BLM on the map of ICD inducing therapies.
Ključne besede: electrochemotherapy, cisplatin, immune response
Objavljeno v DiRROS: 21.03.2024; Ogledov: 74; Prenosov: 40
.pdf Celotno besedilo (7,17 MB)
Gradivo ima več datotek! Več...

3.
4.
Razvoj in karakterizacija mišjega modela za študije HPV-pozitivnega raka glave in vratu
Živa Modic, Maja Čemažar, Boštjan Markelc, Andrej Cör, Gregor Serša, Simona Kranjc Brezar, Tanja Jesenko, 2023, objavljeni povzetek znanstvenega prispevka na konferenci

Ključne besede: miši, rak glave in vratu, gensko zdravljenje
Objavljeno v DiRROS: 19.06.2023; Ogledov: 356; Prenosov: 155
.pdf Celotno besedilo (361,47 KB)
Gradivo ima več datotek! Več...

5.
Aktivacija vzorčno prepoznavnih senzorjev po genskem elektroprenosu plazmida z zapisom za interlevkin-12
Ajda Medved, Tanja Jesenko, Gregor Serša, Maša Omerzel, Maja Čemažar, 2023, objavljeni povzetek znanstvenega prispevka na konferenci

Ključne besede: miši, obsevanje, gensko zdravljenje
Objavljeno v DiRROS: 19.06.2023; Ogledov: 317; Prenosov: 149
.pdf Celotno besedilo (457,33 KB)
Gradivo ima več datotek! Več...

6.
7.
Sproščanje dejavnikov imunogene celične smrti HMGB1 in ATP iz celičnih linij se povečuje s časom po obsevanju
Urša Kešar, Tanja Jesenko, Boštjan Markelc, Katja Uršič Valentinuzzi, Maja Čemažar, Primož Strojan, Gregor Serša, 2023, objavljeni povzetek znanstvenega prispevka na konferenci

Ključne besede: miši, obsevanje, radioterapija
Objavljeno v DiRROS: 19.06.2023; Ogledov: 305; Prenosov: 143
.pdf Celotno besedilo (432,50 KB)
Gradivo ima več datotek! Več...

8.
9.
10.
Iskanje izvedeno v 0.43 sek.
Na vrh